Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Update 2021: Advances and Highlights in Food Allergy: Innovation through a Multi-Targeted Approach
  • +4
  • Sharon Chinthrajah,
  • Sayantani Sindher,
  • Andrew Long,
  • Andrew R. Chin,
  • Angela Hy,
  • Vanitha Sampath,
  • Kari Nadeau
Sharon Chinthrajah
Stanford University

Corresponding Author:[email protected]

Author Profile
Sayantani Sindher
Stanford University
Author Profile
Andrew Long
Stanford University
Author Profile
Andrew R. Chin
Stanford University
Author Profile
Angela Hy
Stanford University
Author Profile
Vanitha Sampath
Stanford University
Author Profile
Kari Nadeau
Stanford University
Author Profile

Abstract

The incidence of food allergy (FA) has continued to rise over the last several decades, posing significant burdens on health and quality of life. Significant strides into the advancement of FA diagnosis, prevention, and treatment have been made in recent years. In an effort to lower reliance on resource-intensive food challenges, the field has continued work toward the development of highly sensitive and specific assays capable of high-throughput analysis to assist in the diagnosis FA. In looking toward early infancy as a critical period in the development of allergy or acquisition of tolerance, evidence has increasingly suggested that early intervention via the early introduction of food allergens and maintenance of skin barrier function may decrease the risk of FA. As such, largescale investigations are underway evaluating infant feeding and the impact of emollient and steroid use in infants with dry skin for the prevention of allergy. On the other end of the spectrum, the past few years have been witness to an explosive increase in clinical trials of novel and innovative therapeutic strategies aimed at the treatment of FA in those whom the disease has already manifested. A milestone in the field, 2020 marked the approval of the first drug, oral peanut allergen, for the indication of peanut allergy. With a foundation of promising data supporting the safety and efficacy of single- and multi-allergen oral immunotherapy, current efforts have turned toward the use of probiotics, biologic agents, and modified allergens to optimize and improve upon existing paradigms. Through these advancements, the field hopes to gain footing in the ongoing battle against FA.
05 May 2022Submitted to Allergy
09 May 2022Submission Checks Completed
09 May 2022Assigned to Editor
09 May 2022Reviewer(s) Assigned
27 May 2022Review(s) Completed, Editorial Evaluation Pending
30 May 2022Editorial Decision: Revise Minor
08 Jun 20221st Revision Received
08 Jun 2022Submission Checks Completed
08 Jun 2022Assigned to Editor
09 Jun 2022Reviewer(s) Assigned
13 Jun 2022Review(s) Completed, Editorial Evaluation Pending
17 Jun 20222nd Revision Received
18 Jun 2022Submission Checks Completed
18 Jun 2022Assigned to Editor
19 Jun 2022Editorial Decision: Accept